Editing Oxycodone (section)

===={{anchor|OxyContin}}Preventive measures====
In August 2010, [[Purdue Pharma]] reformulated their long-acting oxycodone line, marketed as OxyContin, using a polymer, Intac,<ref name=DDD13.8>{{cite web |date=2010 |title=New Abuse Deterrent Formulation Technology for Immediate-Release Opioids |url=http://www.grunenthal.com/cms/cda/file/Drug+Development+%26+Delivery+October+2013+Vol+13+No+8.pdf?fileID=273800346&cacheFix=1383822554000&__k=3870fc7ab9c0252c7a9c8547fb47de75 |url-status=dead |archive-url=https://web.archive.org/web/20151222103656/http://www.grunenthal.com/cms/cda/file/Drug+Development+%26+Delivery+October+2013+Vol+13+No+8.pdf?fileID=273800346&cacheFix=1383822554000&__k=3870fc7ab9c0252c7a9c8547fb47de75 |archive-date=22 December 2015 |access-date=15 December 2015 |website=Grünenthal Group |publisher=Grünenthal Group Worldwide}}</ref> to make the pills more difficult to crush or dissolve in water<ref>{{cite web|vauthors=Diep F|date=13 May 2013|title=How Do You Make a Painkiller Addiction-Proof|url=https://www.popsci.com/science/article/2013-05/science-un-crushable-oxycontin|access-date=30 January 2019|website=Popular Science|publisher=Bonnier Corporation|archive-date=14 December 2019|archive-url=https://web.archive.org/web/20191214154207/https://www.popsci.com/science/article/2013-05/science-un-crushable-oxycontin/|url-status=live}}</ref> to reduce non-medical use of OxyContin.<ref>{{Cite conference|vauthors=Coplan P|year=2012|title=Findings from Purdue's Post-Marketing Epidemiology Studies of Reformulated OxyContin's Effects|url=http://www.nascsa.org/Conference2012/Presentations/Coplan.pdf|conference=NASCSA 2012 Conference|location=Scottsdale, Arizona|archive-url=https://web.archive.org/web/20130614115419/http://www.nascsa.org/Conference2012/Presentations/Coplan.pdf|archive-date=14 June 2013|conference-url=https://web.archive.org/web/20130512052124/http://www.nascsa.org/conference2012.htm|url-status=dead|accessdate=23 May 2013}}</ref> [[Inactive ingredient|Inactive ingredients/excipients]] are [[butylated hydroxytoluene]] (BHT), [[hypromellose]], [[PEG 400|polyethylene glycol 400]], polyethylene oxide, magnesium stearate, and titanium dioxide.<ref name="OxyContin FDA label">{{cite web | title=Oxycontin- oxycodone hydrochloride tablet, film coated, extended release | website=DailyMed | date=5 December 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdfe235-d717-4855-a3c8-a13d26dadede | access-date=7 February 2025}}</ref><ref name="rxlist">{{cite web |title=Oxycontin (Oxycodone HCl): Side Effects, Uses, Dosage, Interactions, Warnings |url=https://www.rxlist.com/oxycontin-drug.htm |website=RxList |language=en}}</ref><ref name=DDD13.8 /> The FDA approved relabeling the reformulated version as abuse-resistant in April 2013.<ref>{{cite press release |title=FDA approves abuse-deterrent labeling for reformulated OxyContin|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm|url-status=dead|archive-url=https://web.archive.org/web/20130520025104/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm|archive-date=20 May 2013|access-date=23 May 2013|publisher=U.S. [[Food and Drug Administration]] (FDA) }}</ref>

[[Pfizer]] manufactures a preparation of short-acting oxycodone, marketed as Oxecta, which contains inactive ingredients, referred to as tamper-resistant Aversion Technology.<ref>{{cite web|title=Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII|url=http://press.pfizer.com/press-release/pfizer-and-acura-announce-fda-approval-oxectatm-oxycodone-hcl-usp-cii|url-status=dead|archive-url=https://web.archive.org/web/20151222111749/http://press.pfizer.com/press-release/pfizer-and-acura-announce-fda-approval-oxectatm-oxycodone-hcl-usp-cii|archive-date=22 December 2015|access-date=15 December 2015|website=Pfizer News and Media|publisher=Pfizer Inc.}}</ref> Approved by the FDA in the U.S. in June 2011, the new formulation, while not being able to deter oral recreational use, makes crushing, chewing, snorting, or injecting the opioid impractical because of a change in its chemical properties.<ref>{{cite web| vauthors = Fiore K |date=20 June 2011|title=FDA Okays New Abuse-Resistant Opioid|url=http://www.medpagetoday.com/ProductAlert/Prescriptions/27157|url-status=dead|archive-url= https://web.archive.org/web/20151222095414/http://www.medpagetoday.com/ProductAlert/Prescriptions/27157|archive-date=22 December 2015|access-date=15 December 2015|website=MedPage Today}}</ref>